Drugs currently approved to treat type 2 diabetes mellitus (T2DM) mostly work by increasing insulin secretion or reducing glucose concentration but are unable to fully improve insulin sensitivity and protect beta-cells [28]. The gene discussed is INS; the disease is type 2 diabetes mellitus.